The IPA Blend combines CJC-1295 without DAC (Mod GRF 1-29, 5mg) with Ipamorelin (10mg) — the standard GHRH + GHRP synergy stack. These two peptides act on completely different receptors on the same pituitary somatotroph cells, producing synergistic (not merely additive) growth hormone pulses that exceed either peptide alone.

Overview

The GHRH + GHRP combination is the most established paradigm in growth hormone secretagogue research. The foundational work by Bowers et al. (1990) demonstrated that co-administration of GHRH with growth hormone-releasing peptides produces GH peaks far exceeding those achieved by either agent alone — a true synergistic effect arising from convergent activation of two independent intracellular signaling cascades on the same somatotroph cell.

The IPA Blend uses CJC-1295 without DAC (Mod GRF 1-29) rather than the DAC-conjugated version, preserving natural pulsatile GH release kinetics. The short half-life (~30 min for CJC-1295, ~2 hours for Ipamorelin) creates a discrete GH pulse that rises and falls within 2-3 hours, mimicking endogenous GH secretory episodes rather than producing the sustained tonic elevation seen with CJC-1295 with DAC.

Ipamorelin was selected as the GHRP component for its clean selectivity profile. Unlike GHRP-6 (which stimulates appetite via ghrelin-like effects and elevates cortisol) or GHRP-2 (which raises prolactin), Ipamorelin releases GH without measurable effects on ACTH, cortisol, prolactin, FSH, LH, or TSH (Raun et al., 1998).

Mechanism of Action

Dual-Receptor Synergy

The two peptides activate independent signaling cascades that converge to amplify GH output:

CJC-1295 → GHRH Receptor Pathway: CJC-1295 binds the GHRH receptor (GHRH-R), a class B GPCR on somatotrophs. This activates Gs → adenylyl cyclase → cAMP → protein kinase A (PKA), which drives GH gene transcription, GH protein synthesis, and priming of secretory vesicles for release. CJC-1295 sets the amplitude baseline — it determines how much GH is available to be released.

Ipamorelin → Ghrelin Receptor Pathway: Ipamorelin activates GHS-R1a, a class A GPCR that couples through Gq/11. This triggers phospholipase C (PLC) → inositol trisphosphate (IP3) + diacylglycerol (DAG) → intracellular calcium mobilization + protein kinase C (PKC) activation. The calcium surge triggers immediate exocytosis of the GH vesicles that CJC-1295 helped synthesize and prime.

Why synergy, not just addition: CJC-1295 fills the gun (GH synthesis and vesicle loading), Ipamorelin pulls the trigger (calcium-dependent exocytosis). Neither pathway alone achieves what both together produce. Additionally, ghrelin receptor activation antagonizes somatostatin signaling at the hypothalamic level, reducing the inhibitory brake on GHRH-driven GH release (Bowers et al., 1990).

Pulsatile vs. Tonic GH Release

The short half-lives of both components ensure GH is released in pulses rather than continuously. This matters because:

• Pulsatile GH is more effective at activating hepatic GH receptors and stimulating IGF-1 production
• Continuous GH elevation leads to GH receptor downregulation and reduced tissue sensitivity
• Pulsatile patterns preserve somatotroph responsiveness — continuous stimulation causes desensitization
• The natural GH pattern consists of 6-12 pulses per day; this blend adds to rather than replaces that pattern

Reconstitution Calculator

Research

Safety Profile

Both components have established safety profiles. Ipamorelin is the most selective GH secretagogue characterized, with no significant cortisol, ACTH, or prolactin perturbation (Raun et al., 1998). CJC-1295 (no DAC) has a short half-life limiting cumulative exposure. Reported observations include transient injection-site reactions, mild flushing, water retention, and transient changes in appetite or blood glucose. As with all GH secretagogues, potential concerns include effects on glucose metabolism and theoretical risk of promoting growth in pre-existing neoplasms.

Pharmacokinetic Profile